Shay Shemesh
Oprichter bij NUVECTIS PHARMA, INC.
Vermogen: 10 M $ op 31-05-2024
Actieve functies van Shay Shemesh
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
NUVECTIS PHARMA, INC. | Operationeel Directeur | 27-07-2020 | - |
Oprichter | 27-07-2020 | - | |
Corporate Officer/Principal | 27-07-2020 | - |
Loopbaan van Shay Shemesh
Eerdere bekende functies van Shay Shemesh
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
STEMLINE THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-2015 | 01-01-2020 |
Algemeen Adviseur | 01-01-2015 | 01-01-2020 | |
KERYX BIOPHARMACEUTICALS | Hoofd Techniek/Wetenschap/O&O | - | - |
Opleiding van Shay Shemesh
Bar-Ilan University | Graduate Degree |
Statistieken
Internationaal
Verenigde Staten | 4 |
Israël | 2 |
Operationeel
Chief Tech/Sci/R&D Officer | 2 |
Chief Operating Officer | 1 |
Founder | 1 |
Sectoraal
Health Technology | 4 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
NUVECTIS PHARMA, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
- Beurs
- Insiders
- Shay Shemesh
- Ervaring